New drug aims to shrink tumors in Hard-to-Treat skin cancer

NCT ID NCT07529405

Not yet recruiting Disease control Sponsor: Virogen Biotechnology Inc. Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated May 23, 2026 · Updated 8 times

Summary

This study tests a new drug, VG712, in people with a rare type of skin lymphoma called mycosis fungoides that has not responded to at least two prior treatments. The drug works by targeting and killing certain immune cells that drive the disease. About 386 adults will be randomly assigned to receive either VG712 or another standard drug (mogamulizumab) to see which is safer and more effective at controlling the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MYCOSIS FUNGOIDES